These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 9116302)

  • 1. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.
    Styles LA; Lubin B; Vichinsky E; Lawrence S; Hua M; Test S; Kuypers F
    Blood; 1997 Apr; 89(7):2554-9. PubMed ID: 9116302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease.
    Odièvre MH; Bony V; Benkerrou M; Lapouméroulie C; Alberti C; Ducrocq R; Jacqz-Aigrain E; Elion J; Cartron JP
    Haematologica; 2008 Apr; 93(4):502-10. PubMed ID: 18322255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties.
    Gambero S; Canalli AA; Traina F; Albuquerque DM; Saad ST; Costa FF; Conran N
    Eur J Haematol; 2007 Feb; 78(2):144-51. PubMed ID: 17313560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea.
    Cartron JP; Elion J
    Transfus Clin Biol; 2008; 15(1-2):39-50. PubMed ID: 18515167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
    Borba R; Lima CS; Grotto HZ
    J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
    Covas DT; de Lucena Angulo I; Vianna Bonini Palma P; Zago MA
    Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nonexpression of CD36 on reticulocytes and mature red blood cells does not modify the clinical course of patients with sickle cell anemia.
    Lee K; Gane P; Roudot-Thoraval F; Godeau B; Bachir D; Bernaudin F; Cartron JP; Galactéros F; Bierling P
    Blood; 2001 Aug; 98(4):966-71. PubMed ID: 11493440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VLA-4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow.
    White J; Krishnamoorthy S; Gupta D; Lancelot M; Moore N; Sarnaik S; Hobbs WE; Light DR; Hines P
    Br J Haematol; 2016 Sep; 174(6):970-82. PubMed ID: 27291690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
    Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA
    Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phorbol ester stimulation increases sickle erythrocyte adherence to endothelium: a novel pathway involving alpha 4 beta 1 integrin receptors on sickle reticulocytes and fibronectin.
    Kumar A; Eckmam JR; Swerlick RA; Wick TM
    Blood; 1996 Dec; 88(11):4348-58. PubMed ID: 8943872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
    Haynes J; Obiako B; Hester RB; Baliga BS; Stevens T
    Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H379-85. PubMed ID: 17993595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaco-proteomic study of hydroxyurea-induced modifications in the sickle red blood cell membrane proteome.
    Ghatpande SS; Choudhary PK; Quinn CT; Goodman SR
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1510-7. PubMed ID: 18849548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells.
    Brun M; Bourdoulous S; Couraud PO; Elion J; Krishnamoorthy R; Lapoumeroulie C
    Pharmacogenomics J; 2003; 3(4):215-26. PubMed ID: 12931135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
    J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD36-positive stress reticulocytosis in sickle cell anemia.
    Browne PV; Hebbel RP
    J Lab Clin Med; 1996 Apr; 127(4):340-7. PubMed ID: 8656036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran/basal cell adhesion molecule (Lu/BCAM) through phosphodiesterase 4A activation.
    Chaar V; Laurance S; Lapoumeroulie C; Cochet S; De Grandis M; Colin Y; Elion J; Le Van Kim C; El Nemer W
    J Biol Chem; 2014 Apr; 289(16):11512-11521. PubMed ID: 24616094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of TNF-alpha-induced sickle RBC retention in retina by a VLA-4 antagonist.
    Lutty GA; Taomoto M; Cao J; McLeod DS; Vanderslice P; McIntyre BW; Fabry ME; Nagel RL
    Invest Ophthalmol Vis Sci; 2001 May; 42(6):1349-55. PubMed ID: 11328750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein IV-independent adhesion of sickle red blood cells to immobilized thrombospondin under flow conditions.
    Joneckis CC; Shock DD; Cunningham ML; Orringer EP; Parise LV
    Blood; 1996 Jun; 87(11):4862-70. PubMed ID: 8639860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
    Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
    Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.